Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 8/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3667316 | 0.93 | PDCD1 (0.39) | PRMT6AOC3EPHX2PDCD1CD274 | |
| SCHEMBL3672635 | 0.85 | SIGMAR1 (0.36) | PRMT6SIGMAR1ACKR3ACHEBCHE | |
| SCHEMBL4173616 | 0.84 | PRMT6 (0.42) | PRMT6AOC3ACHEBCHE | |
| SCHEMBL3667382 | 0.82 | HTR7 (0.43) | PRMT6AOC3EPHX2 | |
| SCHEMBL4155263 | 0.81 | AOC3 (0.43) | AOC3CD274 | |
| SCHEMBL3724516 | 0.78 | AOC3 (0.41) | PRMT6AOC3EPHX2 | |
| SCHEMBL3666218 | 0.78 | PRKCI (0.56) | PRMT6EPHX2PRKCI | |
| SCHEMBL3670575 | 0.77 | LTA4H (0.38) | PRMT6PDCD1CD274 | |
| SCHEMBL3664072 | 0.76 | SCN8A (0.46) | PRMT6EPHX2BCHEPDCD1CD274 | |
| SCHEMBL13778428 | 0.73 | PRMT6 (0.44) | PRMT6AOC3PDCD1CD274PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | claimed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | PRMT6 1956/4885AOC3 3251/4885SIGMAR1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.